<DOC>
	<DOCNO>NCT01152242</DOCNO>
	<brief_summary>The purpose study evaluate whether within-subject variation duration action time-action profile glargine measure isoglycemic clamp prespecified level .</brief_summary>
	<brief_title>Pharmacodynamic Pharmacokinetic Variability Basal Insulin ( 0000-168 )</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Part 1 : Patient male 18 45 year age ( inclusive ) prestudy ( screen ) visit Patient clinical diagnosis type 1 diabetes Patient must treat insulin since diagnosis stable dose insulin Patient Body Mass Index ( BMI ) &lt; =27 kg/m2 &gt; 18 kg/m2 Patient nonsmoker and/or use nicotine nicotinecontaining product least approximately 6 month Part 2 : Subject male 18 45 year age prestudy ( screen ) visit Subject Body Mass Index ( BMI ) &lt; =25 kg/m^2 Subject nonsmoker and/or use nicotine nicotinecontaining product least approximately 6 month Part 1 : Patient history stroke , chronic seizure , major neurological disorder Patient currently active untreated clinically significant endocrine , cardiovascular , hematological , hepatic , renal , respiratory , genitourinary abnormality diseases Patient history hypertension require treatment Patient history neoplastic disease within past 5 year Patient currently treat , history treatment oral antihyperglycemic agent Patient history significant multiple and/or severe allergy Part 2 : Subject history stroke , chronic seizure , major neurological disorder Subject history hypertension require treatment Subject history neoplastic disease within past 5 year Subject history diabetes ( Type 1 , Type 2 steroidinduced ) family history diabetes mellitus Subject history hypersensitivity glargine inactive ingredient</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Insulin</keyword>
</DOC>